A bioluminescent assay for measuring glucose uptake

详细信息    查看全文

• 作者：Michael P. Valley^a ; ^{mike.valley@promega.com" class="auth_mail" title="E-mail the corresponding author} ; Natasha Karassina^a ; Natsuyo Aoyama^b ; Coby Carlson^b ; James J. Cali^a ; Jolanta Vidugiriene^a
• 关键词：Bioluminescent ; Glucose uptake
• 刊名：Analytical Biochemistry
• 出版年：2016
• 出版时间：15 July 2016
• 年：2016
• 卷：505
• 期：Complete
• 页码：43-50
• 全文大小：961 K

文摘

Identifying activators and inhibitors of glucose uptake is critical for both diabetes management and anticancer therapy. To facilitate such studies, easy-to-use nonradioactive assays are desired. Here we describe a bioluminescent glucose uptake assay for measuring glucose transport in cells. The assay is based on the uptake of 2-deoxyglucose and the enzymatic detection of the 2-deoxyglucose-6-phosphate that accumulates. Uptake can be measured from a variety of cell types, it can be inhibited by known glucose transporter inhibitors, and the bioluminescent assay yields similar results when compared with the radioactive method. With HCT 116 cells, glucose uptake can be detected in as little as 5000 cells and remains linear up to 50,000 cells with signal-to-background values ranging from 5 to 45. The assay can be used to screen for glucose transporter inhibitors, or by multiplexing with viability readouts, changes in glucose uptake can be differentiated from overall effects on cell health. The assay also can provide a relevant end point for measuring insulin sensitivity. With adipocytes and myotubes, insulin-dependent increases in glucose uptake have been measured with 10- and 2-fold assay windows, respectively. Significant assay signals of 2-fold or more have also been measured with human induced pluripotent stem cell (iPSC)-derived cardiomyocytes and skeletal myoblasts.